In the context of non-alcoholic fatty liver disease (NAFLD), characterized by dysregulated lipid metabolism in hepatocytes, the quest for safe and effective therapeutics targeting lipid metabolism has gained paramount...In the context of non-alcoholic fatty liver disease (NAFLD), characterized by dysregulated lipid metabolism in hepatocytes, the quest for safe and effective therapeutics targeting lipid metabolism has gained paramount importance. Sanhuang Xiexin Tang (SXT) and Baihu Tang (BHT) have emerged as prominent candidates for treating metabolic disorders. SXT combined with BHT plus Cangzhu (SBC) has been used clinically for Weihuochisheng obese patients. This retrospective analysis focused on assessing the anti-obesity effects of SBC in Weihuochisheng obese patients. We observed significant reductions in body weight and hepatic lipid content among obese patients following SBC treatment. To gain further insights, we investigated the effects and underlying mechanisms of SBC in HFD-fed mice. The results demonstrated that SBC treatment mitigated body weight gain and hepatic lipid accumulation in HFD-fed mice. Pharmacological network analysis suggested that SBC may affect lipid metabolism, mitochondria, inflammation, and apoptosis—a hypothesis supported by the hepatic transcriptomic analysis in HFD-fed mice treated with SBC. Notably, SBC treatment was associated with enhanced hepatic mitochondrial biogenesis and the inhibition of the c-Jun N-terminal kinase (JNK)/nuclear factor-kappa B (NF-κB) and extracellular signal-regulated kinase (ERK)/NF-κB pathways. In conclusion, SBC treatment alleviates NAFLD in both obese patients and mouse models by improving lipid metabolism, potentially through enhancing mitochondrial biogenesis. These effects, in turn, ameliorate inflammation in hepatocytes.展开更多
目的基于分类树模型对乙型肝炎相关慢加急性肝衰竭患者发生肝性脑病的影响因素和高危人群进行研究,建立评估慢加急性肝衰竭患者发生肝性脑病风险的分类树模型和简易风险评估表。方法收集2010年1月—2018年6月在佛山市第一人民医院感染...目的基于分类树模型对乙型肝炎相关慢加急性肝衰竭患者发生肝性脑病的影响因素和高危人群进行研究,建立评估慢加急性肝衰竭患者发生肝性脑病风险的分类树模型和简易风险评估表。方法收集2010年1月—2018年6月在佛山市第一人民医院感染科、江门市中心医院感染科和南方医科大学顺德医院感染性疾病科住院治疗的乙型肝炎相关慢加急性肝衰竭患者的临床资料,利用分类树模型探索肝性脑病的影响因素和高危人群。结果多因素logistic回归分析提示年龄(回归系数=0.035,P=0.001,OR=1.036)、肝肾综合征(回归系数=1.295,P=0.023,OR=3.650)和Model for end-stage liver disease(MELD)评分(回归系数=0.750,P=0.003,OR=2.117)为慢加急性肝衰竭患者发生肝性脑病的独立影响因素。分类树模型提示慢加急性肝衰竭患者发生肝性脑病和MELD评分、年龄有关。通过MELD评分和年龄可建立评估慢加急性肝衰竭患者发生肝性脑病风险的简易风险评估表。结论通过多因素logistic回归分析和分类树模型发现慢加急性肝衰竭患者发生肝性脑病和MELD评分、年龄关系密切,根据这2个指标建立的分类树模型和简单风险评估表可用于评估慢加急性肝衰竭患者发生肝性脑病的风险。展开更多
基金supported by grants from the National Key R&D Program of China(2017YFA0105803)the National Natural Science Foundation of China(82270886,82070811)+2 种基金the Science and Technology Plan Project of Guangzhou City(202007040003,202201020497)the 5010 Clinical Research Projects of Sun Yat-Sen University(2015015)the Dengfeng Plan High-level Hospital Construction Opening Project of Foshan Fourth People's Hospital(FSSYKF-2020011 and FSSYKF-2020009)。
文摘In the context of non-alcoholic fatty liver disease (NAFLD), characterized by dysregulated lipid metabolism in hepatocytes, the quest for safe and effective therapeutics targeting lipid metabolism has gained paramount importance. Sanhuang Xiexin Tang (SXT) and Baihu Tang (BHT) have emerged as prominent candidates for treating metabolic disorders. SXT combined with BHT plus Cangzhu (SBC) has been used clinically for Weihuochisheng obese patients. This retrospective analysis focused on assessing the anti-obesity effects of SBC in Weihuochisheng obese patients. We observed significant reductions in body weight and hepatic lipid content among obese patients following SBC treatment. To gain further insights, we investigated the effects and underlying mechanisms of SBC in HFD-fed mice. The results demonstrated that SBC treatment mitigated body weight gain and hepatic lipid accumulation in HFD-fed mice. Pharmacological network analysis suggested that SBC may affect lipid metabolism, mitochondria, inflammation, and apoptosis—a hypothesis supported by the hepatic transcriptomic analysis in HFD-fed mice treated with SBC. Notably, SBC treatment was associated with enhanced hepatic mitochondrial biogenesis and the inhibition of the c-Jun N-terminal kinase (JNK)/nuclear factor-kappa B (NF-κB) and extracellular signal-regulated kinase (ERK)/NF-κB pathways. In conclusion, SBC treatment alleviates NAFLD in both obese patients and mouse models by improving lipid metabolism, potentially through enhancing mitochondrial biogenesis. These effects, in turn, ameliorate inflammation in hepatocytes.
文摘目的基于分类树模型对乙型肝炎相关慢加急性肝衰竭患者发生肝性脑病的影响因素和高危人群进行研究,建立评估慢加急性肝衰竭患者发生肝性脑病风险的分类树模型和简易风险评估表。方法收集2010年1月—2018年6月在佛山市第一人民医院感染科、江门市中心医院感染科和南方医科大学顺德医院感染性疾病科住院治疗的乙型肝炎相关慢加急性肝衰竭患者的临床资料,利用分类树模型探索肝性脑病的影响因素和高危人群。结果多因素logistic回归分析提示年龄(回归系数=0.035,P=0.001,OR=1.036)、肝肾综合征(回归系数=1.295,P=0.023,OR=3.650)和Model for end-stage liver disease(MELD)评分(回归系数=0.750,P=0.003,OR=2.117)为慢加急性肝衰竭患者发生肝性脑病的独立影响因素。分类树模型提示慢加急性肝衰竭患者发生肝性脑病和MELD评分、年龄有关。通过MELD评分和年龄可建立评估慢加急性肝衰竭患者发生肝性脑病风险的简易风险评估表。结论通过多因素logistic回归分析和分类树模型发现慢加急性肝衰竭患者发生肝性脑病和MELD评分、年龄关系密切,根据这2个指标建立的分类树模型和简单风险评估表可用于评估慢加急性肝衰竭患者发生肝性脑病的风险。